Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles

Perry T. Yin, Thanapat Pongkulapa, Hyeon Yeol Cho, Jiyou Han, Nicholas J. Pasquale, Hudifah Rabie, Jong-Hoon Kim, Jeong Woo Choi, Ki Bum Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In this study, we report the use of a multifunctional magnetic core-shell nanoparticle (MCNP), composed of a highly magnetic zinc-doped iron oxide (ZnFe2O4) core nanoparticle and a biocompatible mesoporous silica (mSi) shell, for the simultaneous delivery of let-7a microRNA (miRNA) and anticancer drugs (e.g., doxorubicin) to overcome chemoresistance in breast cancer. Owing to the ability of let-7a to repress DNA repair mechanisms (e.g., BRCA1 and BRCA2) and downregulate drug efflux pumps (e.g., ABCG2), delivery of let-7a could sensitize chemoresistant breast cancer cells (MDA-MB-231) to subsequent doxorubicin chemotherapy both in vitro and in vivo. Moreover, the multifunctionality of our MCNPs allows for the monitoring of in vivo delivery via magnetic resonance imaging. In short, we have developed a multifunctional MCNP-based therapeutic approach to provide an attractive method with which to enhance our ability not only to deliver combined miRNA therapeutics with small-molecule drugs in both selective and effective manner but also to sensitize cancer cells for the enhanced treatment via the combination of miRNA replacement therapy using a single nanoplatform.

Original languageEnglish
Pages (from-to)26954-26963
Number of pages10
JournalACS Applied Materials and Interfaces
Volume10
Issue number32
DOIs
Publication statusPublished - 2018 Aug 15

Fingerprint

Magnetic cores
MicroRNAs
Nanoparticles
Doxorubicin
Cells
Pharmaceutical Preparations
Chemotherapy
Magnetic resonance
Iron oxides
Silicon Dioxide
Zinc
DNA
Repair
Silica
Pumps
Imaging techniques
Molecules
Monitoring

Keywords

  • chemoresistance
  • combination cancer therapy
  • magnetic core-shell nanoparticles
  • microRNA therapeutics
  • targeted delivery

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles. / Yin, Perry T.; Pongkulapa, Thanapat; Cho, Hyeon Yeol; Han, Jiyou; Pasquale, Nicholas J.; Rabie, Hudifah; Kim, Jong-Hoon; Choi, Jeong Woo; Lee, Ki Bum.

In: ACS Applied Materials and Interfaces, Vol. 10, No. 32, 15.08.2018, p. 26954-26963.

Research output: Contribution to journalArticle

Yin, Perry T. ; Pongkulapa, Thanapat ; Cho, Hyeon Yeol ; Han, Jiyou ; Pasquale, Nicholas J. ; Rabie, Hudifah ; Kim, Jong-Hoon ; Choi, Jeong Woo ; Lee, Ki Bum. / Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles. In: ACS Applied Materials and Interfaces. 2018 ; Vol. 10, No. 32. pp. 26954-26963.
@article{6398442364924f21992fc255b4145f79,
title = "Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles",
abstract = "In this study, we report the use of a multifunctional magnetic core-shell nanoparticle (MCNP), composed of a highly magnetic zinc-doped iron oxide (ZnFe2O4) core nanoparticle and a biocompatible mesoporous silica (mSi) shell, for the simultaneous delivery of let-7a microRNA (miRNA) and anticancer drugs (e.g., doxorubicin) to overcome chemoresistance in breast cancer. Owing to the ability of let-7a to repress DNA repair mechanisms (e.g., BRCA1 and BRCA2) and downregulate drug efflux pumps (e.g., ABCG2), delivery of let-7a could sensitize chemoresistant breast cancer cells (MDA-MB-231) to subsequent doxorubicin chemotherapy both in vitro and in vivo. Moreover, the multifunctionality of our MCNPs allows for the monitoring of in vivo delivery via magnetic resonance imaging. In short, we have developed a multifunctional MCNP-based therapeutic approach to provide an attractive method with which to enhance our ability not only to deliver combined miRNA therapeutics with small-molecule drugs in both selective and effective manner but also to sensitize cancer cells for the enhanced treatment via the combination of miRNA replacement therapy using a single nanoplatform.",
keywords = "chemoresistance, combination cancer therapy, magnetic core-shell nanoparticles, microRNA therapeutics, targeted delivery",
author = "Yin, {Perry T.} and Thanapat Pongkulapa and Cho, {Hyeon Yeol} and Jiyou Han and Pasquale, {Nicholas J.} and Hudifah Rabie and Jong-Hoon Kim and Choi, {Jeong Woo} and Lee, {Ki Bum}",
year = "2018",
month = "8",
day = "15",
doi = "10.1021/acsami.8b09086",
language = "English",
volume = "10",
pages = "26954--26963",
journal = "ACS applied materials & interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "32",

}

TY - JOUR

T1 - Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles

AU - Yin, Perry T.

AU - Pongkulapa, Thanapat

AU - Cho, Hyeon Yeol

AU - Han, Jiyou

AU - Pasquale, Nicholas J.

AU - Rabie, Hudifah

AU - Kim, Jong-Hoon

AU - Choi, Jeong Woo

AU - Lee, Ki Bum

PY - 2018/8/15

Y1 - 2018/8/15

N2 - In this study, we report the use of a multifunctional magnetic core-shell nanoparticle (MCNP), composed of a highly magnetic zinc-doped iron oxide (ZnFe2O4) core nanoparticle and a biocompatible mesoporous silica (mSi) shell, for the simultaneous delivery of let-7a microRNA (miRNA) and anticancer drugs (e.g., doxorubicin) to overcome chemoresistance in breast cancer. Owing to the ability of let-7a to repress DNA repair mechanisms (e.g., BRCA1 and BRCA2) and downregulate drug efflux pumps (e.g., ABCG2), delivery of let-7a could sensitize chemoresistant breast cancer cells (MDA-MB-231) to subsequent doxorubicin chemotherapy both in vitro and in vivo. Moreover, the multifunctionality of our MCNPs allows for the monitoring of in vivo delivery via magnetic resonance imaging. In short, we have developed a multifunctional MCNP-based therapeutic approach to provide an attractive method with which to enhance our ability not only to deliver combined miRNA therapeutics with small-molecule drugs in both selective and effective manner but also to sensitize cancer cells for the enhanced treatment via the combination of miRNA replacement therapy using a single nanoplatform.

AB - In this study, we report the use of a multifunctional magnetic core-shell nanoparticle (MCNP), composed of a highly magnetic zinc-doped iron oxide (ZnFe2O4) core nanoparticle and a biocompatible mesoporous silica (mSi) shell, for the simultaneous delivery of let-7a microRNA (miRNA) and anticancer drugs (e.g., doxorubicin) to overcome chemoresistance in breast cancer. Owing to the ability of let-7a to repress DNA repair mechanisms (e.g., BRCA1 and BRCA2) and downregulate drug efflux pumps (e.g., ABCG2), delivery of let-7a could sensitize chemoresistant breast cancer cells (MDA-MB-231) to subsequent doxorubicin chemotherapy both in vitro and in vivo. Moreover, the multifunctionality of our MCNPs allows for the monitoring of in vivo delivery via magnetic resonance imaging. In short, we have developed a multifunctional MCNP-based therapeutic approach to provide an attractive method with which to enhance our ability not only to deliver combined miRNA therapeutics with small-molecule drugs in both selective and effective manner but also to sensitize cancer cells for the enhanced treatment via the combination of miRNA replacement therapy using a single nanoplatform.

KW - chemoresistance

KW - combination cancer therapy

KW - magnetic core-shell nanoparticles

KW - microRNA therapeutics

KW - targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=85051597488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051597488&partnerID=8YFLogxK

U2 - 10.1021/acsami.8b09086

DO - 10.1021/acsami.8b09086

M3 - Article

VL - 10

SP - 26954

EP - 26963

JO - ACS applied materials & interfaces

JF - ACS applied materials & interfaces

SN - 1944-8244

IS - 32

ER -